A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase of Trial: Phase III
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Trebananib (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRINOVA-2; TRINOVA-2
- Sponsors Amgen
- 18 Jun 2017 This trial has been completed in Belgium.
- 03 Jun 2017 This trial has been completed in Hungary & Greece (End date:2017-04-19).
- 02 Jun 2017 This trial has been completed in Austria (end date: 19 Apr 2017).